学术周报 · IF≥10
肾内科领域文献阅读汇编
2026年第44周 (2026-10-31) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
★本周 Top 10 高影响力文献
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| European journal of preventive cardiology | 2 | IF 10.0 |
| Diabetes care | 2 | IF 22.6 |
| Ageing research reviews | 1 | IF 15.5 |
| Endocrine reviews | 1 | IF 23.9 |
| ACS sensors | 1 | IF 10.9 |
| Kidney international | 1 | IF 21.8 |
| Circulation research | 1 | IF 18.0 |
| Annual review of medicine | 1 | IF 18.8 |
| Science translational medicine | 1 | IF 15.6 |
| European journal of heart failure | 1 | IF 10.3 |
1慢性肾脏病 CKD (4篇)
临床研究 (2篇)
Glucagon-like peptide-1 receptor agonists (GLP-1RA) are a novel class of anti-diabetic drugs that can treat obesity and type 2 diabetes (T2D). T2D and chronic viral hepatitis (CVH) frequently coexist and worsen liver and non-liver outcomes, but effective pharmacological therapies are limited. We aimed to evaluate the effect of GLP-1RA on liver and non-liver complications among patients with T2D and CVH in the United States. Patients with T2D and CVH initiating GLP-1RA were included (2013-2022) in Merative™ Marketscan® Research Databases. Primary outcomes included (1) hepatocellular carcinoma (HCC) and cirrhosis, and (2) cardiovascular disease (CVD), chronic kidney disease (CKD), and non-liver cancer. Cox proportional hazards models were conducted to estimate hazard ratio (HR) and 95% confidence interval (CI). A total of 9,499 patients with T2D and CVH were included after 1:4 propensity score matching. Compared with non-GLP-1RA (N=7,366), GLP-1RA use (N=2,133) was associated with significantly lower risks of any liver-related outcomes (HR 0.71, 95% CI 0.57-0.87; P=0.001), HCC (HR 0.53, 95% CI 0.31-0.93; P=0.028), cirrhosis (HR 0.70, 95% CI 0.56-0.86; P<0.001), CKD (HR 0.67, 95% CI 0.53-0.84; P<0.001). A trend toward a lower risk of CVD (HR 0.82, 95% CI 0.66-1.03; P=0.089) and non-liver cancer (HR 0.73, 95% CI 0.53-1.01; P=0.055) was observed among GLP-1RA users, although the association did not reach statistical significance. GLP-1RA use was associated with lower risks of cirrhosis, HCC, and CKD among patients with T2D and CVH, with nonsignificant trends toward lower risks of CVD and non-liver cancer.
中文摘要:胰高血糖素样肽-1受体激动剂(GLP-1RA)是一类新型降糖药,可治疗肥胖和2型糖尿病(T2D)。T2D与慢性病毒性肝炎(CVH)常并存,并加重肝脏及非肝脏结局,但有效的药物治疗有限。研究旨在评估美国T2D合并CVH患者使用GLP-1RA对肝脏和非肝脏并发症的影响。纳入2013—2022年Merative™ Marketscan® Research Databases中起始GLP-1RA治疗的T2D合并CVH患者。主要结局包括(1)肝细胞癌(HCC)和肝硬化,(2)心血管疾病(CVD)、慢性肾脏病(CKD)和非肝癌。采用Cox比例风险模型估计风险比(HR)和95%置信区间(CI)。经1:4倾向评分匹配后,共纳入9,499例T2D合并CVH患者。与非GLP-1RA组(N=7,366)相比,GLP-1RA使用组(N=2,133)任何肝脏相关结局风险显著降低(HR 0.71,95% CI 0.57-0.87;P=0.001),HCC风险(HR 0.53,95% CI 0.31-0.93;P=0.028)、肝硬化风险(HR 0.70,95% CI 0.56-0.86;P<0.001)、CKD风险(HR 0.67,95% CI 0.53-0.84;P<0.001)亦显著降低。GLP-1RA使用者中观察到CVD风险(HR 0.82,95% CI 0.66-1.03;P=0.089)和非肝癌风险(HR 0.73,95% CI 0.53-1.01;P=0.055)有降低趋势,但关联未达到统计学显著性。在T2D合并CVH患者中,GLP-1RA使用与肝硬化、HCC和CKD风险降低相关,CVD和非肝癌风险呈非显著降低趋势。
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are agents originally developed as glucose-lowering drugs but now widely used to improve cardiorenal outcomes, including in patients with heart failure and chronic kidney disease regardless of diabetes status. However, their exact mode of action remains unclear. Here, we investigated the association of loss-of-function (LoF) and other rare coding variants in the SLC5A2 gene, as a genetic model of altered SGLT2 function, with 13 cardiometabolic and renal traits and clinical outcomes. A total of 442 570 European ancestry participants from the UK Biobank with exome sequence and phenotype data were included. We applied SAIGE-GENE+ for gene-based and single-variant association tests in the full study population and in individuals with heart failure, renal failure, and type 2 diabetes (T2D). A total of 52 LoF variants in SLC5A2 were identified. Rare variants in SLC5A2 were associated with decreased uric acid (PCauchy = 4.98 × 10-13) and with increased haematocrit (PCauchy = 1.67 × 10-5), haemoglobin (PCauchy = 1.60 × 10-5), and estimated glomerular filtration rate (PCauchy = 9.88 × 10-4). One frameshift variant (rs267607067) was significantly associated with increased haemoglobin (β = 0.33 [95% CI 0.15-0.51]; P-value = 2.40 × 10-4) and another (rs768095044) with decreased uric acid (β = -0.31 [95% CI -0.49 to -0.13]; P-value = 4.22 × 10-4). In patients with T2D, the rare variants within SLC5A2 were also associated with a lower probability of having heart failure (PCauchy = 4.00 × 10-4). Rare genetic variants in SLC5A2 were associated with increased haemoglobin and decreased uric acid. These variants were also associated with a lower probability of heart failure among participants with T2D, providing tentative genetic support for a cardioprotective effect of SGLT2 inhibition.
中文摘要:钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂最初作为降糖药开发,现已广泛用于改善心肾结局,包括心力衰竭和慢性肾脏病患者,无论是否合并糖尿病。但其确切作用机制仍不清楚。将SLC5A2基因的功能缺失(LoF)变异及其他罕见编码变异作为SGLT2功能改变的遗传模型,分析其与13项心脏代谢和肾脏性状及临床结局的关联。纳入英国生物银行442 570名具有外显子组测序和表型数据的欧洲裔参与者。在全部研究人群以及心力衰竭、肾衰竭和2型糖尿病(T2D)个体中,使用SAIGE-GENE+进行基于基因和单变异的关联检验。共鉴定出SLC5A2的52个LoF变异。SLC5A2罕见变异与尿酸降低(P_Cauchy=4.98×10^-13)以及血细胞比容(P_Cauchy=1.67×10^-5)、血红蛋白(P_Cauchy=1.60×10^-5)和估算肾小球滤过率(P_Cauchy=9.88×10^-4)升高相关。一个移码变异(rs267607067)与血红蛋白升高显著相关(β=0.33[95% CI 0.15–0.51];P=2.40×10^-4),另一个变异(rs768095044)与尿酸降低相关(β=-0.31[95% CI -0.49至-0.13];P=4.22×10^-4)。在T2D患者中,SLC5A2内的罕见变异还与较低的心力衰竭患病概率相关(P_Cauchy=4.00×10^-4)。SLC5A2罕见遗传变异与血红蛋白升高和尿酸降低相关。在T2D参与者中,这些变异还与较低的心力衰竭概率相关,为SGLT2抑制的心脏保护作用提供了初步遗传学支持。
基础研究 (2篇)
Non-invasive wearable sensing of sweat uric acid (UA) and urea provides a promising strategy for early chronic kidney disease screening. Nevertheless, most electrochemical sensors for UA and urea detection suffer from insufficient anti-interference and require exogenous redox probes, restricting reagent-free on-body measurement. Herein, we develop a wearable microfluidic electrochemical platform based on Prussian blue-embedded molecularly imprinted polymer (PB-MIP) composite materials for reagent-free, enzyme-free dual-biomarker quantification. Urea-specific and UA-specific PB-MIP composites are prepared via a facile one-step ultraviolet polymerization strategy. PB uniformly embedded within the imprinted framework acts as an intrinsic solid-state redox mediator, integrating specific molecular recognition and built-in electrochemical signal transduction into a single functional material. The two PB-MIP composites are drop-coated on dual working electrodes of a screen-printed carbon electrode, coupled with a capillary-driven microfluidic chip to construct a wearable electrochemical platform. Benefiting from the microfluidic design, the system enables pump-free spontaneous collection of trace sweat samples and achieves simultaneous quantification of sweat UA and urea. The platform exhibits wide linear ranges (0.1-600 μM for uric acid, 0.1-300 mM for urea), low limits of detection, excellent anti-interference capacity, recyclability, and favorable storage stability. On-body dietary intervention tests capture clear postprandial biomarker fluctuations, and detection results show good agreement with HPLC-MS reference values. This work offers a straightforward material-engineering strategy to develop probe-free MIP sensing interfaces and integrated wearable microfluidic devices, showing promising prospects for noninvasive preliminary screening of kidney function.
中文摘要:汗液尿酸(UA)和尿素的无创可穿戴传感为慢性肾脏病早期筛查提供了一种有前景的策略。然而,多数用于UA和尿素检测的电化学传感器抗干扰能力不足,且需要外源性氧化还原探针,限制了无试剂在体测量。为此,我们开发了一种基于普鲁士蓝嵌入分子印迹聚合物(PB-MIP)复合材料的可穿戴微流控电化学平台,用于无试剂、无酶的双标志物定量检测。通过简便的一步紫外聚合策略制备尿素特异性与UA特异性的PB-MIP复合材料。均匀嵌入印迹骨架中的PB作为内置固态氧化还原介体,将特异性分子识别与内置电化学信号转导整合于单一功能材料。将两种PB-MIP复合材料滴涂于丝网印刷碳电极的双工作电极,并与毛细驱动微流控芯片结合,构建可穿戴电化学平台。得益于微流控设计,系统可无泵自发收集微量汗液样本,并实现汗液UA与尿素的同步定量。该平台具有宽线性范围(尿酸0.1-600 μM,尿素0.1-300 mM)、低检出限、良好抗干扰能力、可重复使用性和较好的储存稳定性。在体饮食干预试验捕捉到清晰的餐后标志物波动,检测结果与HPLC-MS参考值一致。这项工作提供了一种直接的材料工程策略,用于开发无探针MIP传感界面和集成式可穿戴微流控器件,在肾功能无创初步筛查方面具有应用前景。
Chronic kidney disease (CKD) increases cardiovascular risk and is linked to arterial stiffening and atherosclerosis. How stiffness promotes atherogenesis remains unclear. DDR1 (discoidin domain receptor 1), a mechanosensory tyrosine kinase receptor, has been implicated in force-regulated arterial remodeling. We investigated whether DDR1-mediated mechanosensation links arterial stiffness to vascular smooth muscle cell (SMC)-endothelial paracrine communication in CKD-related atherosclerosis. Single-cell RNA sequencing, secretome proteomics, and bulk RNA sequencing were integrated with stiffness-controlled models, endothelial assays, and a CKD-hyperlipidemia mouse model. SMC-specific Ddr1 deletion and a DDR1 dephosphorylation-targeting chimera (DEPTAC) were evaluated in vivo. Plasma TSP-1 (thrombospondin-1) levels were quantified in a CKD clinical cohort and analyzed in relation to renal function and atherosclerosis severity. CKD-associated vascular stiffening coincided with SMC phenotypic switching and enhanced THBS signaling. Multiomics integration identified THBS1 as a stiffness-induced SMC secretory effector. Stiff matrices increased SMC THBS1 secretion, promoting endothelial proliferation, migration, and leukocyte adhesion; these effects were attenuated by THBS1 knockdown. DDR1 coupled matrix stiffness cues to THBS1 expression by regulating its transcription via a tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon-FOXO3 (forkhead box O3) axis. Vascular SMC-specific Ddr1 deletion reduced aortic THBS1 levels, vascular stiffening, and atherosclerotic burden. DEPTAC suppressed aberrant DDR1 phosphorylation, reduced THBS1, and ameliorated vascular stiffening and atherosclerosis. Plasma THBS1 increased with CKD severity and correlated with atherosclerosis. DDR1-dependent mechanosensing in SMCs drives stiffness-induced paracrine signaling to endothelium via THBS1, promoting CKD-accelerated atherosclerosis. Targeting mechanical DDR1 activation may be therapeutic.
中文摘要:慢性肾脏病(CKD)增加心血管风险,并与动脉僵硬和动脉粥样硬化相关。僵硬如何促进动脉粥样硬化形成仍不清楚。DDR1(盘状结构域受体1)是一种机械感知酪氨酸激酶受体,已被认为参与力调控的动脉重塑。我们探讨了DDR1介导的机械感知是否将动脉僵硬与CKD相关动脉粥样硬化中的血管平滑肌细胞(SMC)与内皮细胞旁分泌通讯联系起来。研究整合了单细胞RNA测序、分泌组蛋白质组学和批量RNA测序,并结合刚度控制模型、内皮细胞实验和CKD合并高脂血症小鼠模型。在体内评估了SMC特异性Ddr1缺失和靶向DDR1去磷酸化的嵌合体(DEPTAC)。在CKD临床队列中定量血浆TSP-1(凝血酶敏感蛋白1)水平,并分析其与肾功能和动脉粥样硬化严重程度的关系。CKD相关血管僵硬与SMC表型转换及THBS信号增强同时出现。多组学整合将THBS1鉴定为刚度诱导的SMC分泌效应分子。硬基质增加SMC的THBS1分泌,促进内皮细胞增殖、迁移和白细胞黏附;THBS1敲低可减弱这些效应。DDR1通过酪氨酸3-单加氧酶/色氨酸5-单加氧酶激活蛋白ε-FOXO3(叉头盒O3)轴调控THBS1转录,将基质刚度线索与THBS1表达偶联。血管SMC特异性Ddr1缺失降低主动脉THBS1水平、血管僵硬和动脉粥样硬化负荷。DEPTAC抑制异常DDR1磷酸化,降低THBS1,并改善血管僵硬和动脉粥样硬化。血浆THBS1随CKD严重程度升高,并与动脉粥样硬化相关。SMC中DDR1依赖性机械感知通过THBS1驱动刚度诱导的向内皮旁分泌信号,促进CKD加速的动脉粥样硬化。靶向DDR1机械激活可能具有治疗作用。
2透析 (3篇)
临床研究 (3篇)
The default therapy for end-stage kidney disease is often dialysis, but for those with advanced age and multimorbidity, it may not provide significant benefit to longevity or quality of life. Conservative management (CM) is a holistic care pathway for those whose care preferences do not align with dialysis. CM aims to optimize quality of life over the disease course as patient priorities evolve and their disease progresses. Components of CM include customized chronic kidney disease care, symptom management, and navigation of transitions of care, including end-of-life care. Nephrology clinicians are the central providers of CM and ideally collaborate with a multidisciplinary team to provide medical, psychosocial, and spiritual care.
中文摘要:终末期肾病的默认治疗常为透析,但对高龄且合并多种疾病者,透析未必能显著改善寿命或生活质量。保守管理(CM)是一条整体照护路径,适用于照护偏好与透析不相符的患者。CM 的目标是在患者优先级变化与疾病进展过程中优化生活质量。CM 的组成包括个体化的慢性肾脏病照护、症状管理,以及照护转衔的引导,含临终照护。肾脏科临床医生是 CM 的核心提供者,理想情况下与多学科团队协作,提供医疗、心理社会与灵性照护。
Advanced heart failure (AdvHF) remains a major clinical challenge, yet contemporary epidemiological real-world data on AdvHF patients are limited. The aim was to assess 20-year trends in clinical characteristics, outcomes, and use of left ventricular assist devices (LVAD) and heart transplantation (HTx) in patients with AdvHF and reduced ejection fraction (AdvHFrEF) in Sweden. Between 2003 and 2022, 5323 patients (median age 76 [IQR 68-82], 23% females) included in the Swedish HF Registry met adapted ESC-HFA criteria for AdvHF (NYHA III-IV, EF <30%, ≥1 HF hospitalization ≤6 months). Of these, 29% were eligible for AdvHF therapies (median age 63 [IQR 57-67] years, 18% females) according to the following additional criteria: ≤70 years old, no dialysis within ≤5 years, no active cancer within ≤3 years.Unadjusted temporal trends in 1-year outcomes (all-cause, CV and non-CV death, HTx, and LVAD implantation) were presented as estimated annual percent change (eAPC). 1-year all-cause mortality declined significantly in the overall cohort (eAPC -3.8; 95%CI -5.3 to -2.2) as well as in patients eligible for AdvHF therapies (eAPC -3.2; 95%CI -6.3 to -0.1) over the study period. These improvements were largely driven by reductions in CV mortality (overall cohort: eAPC -4.3; 95%CI -6.0 to -2.6; eligible cohort: eAPC -5.6, 95%CI -9.4 to -1.7). Use of LVAD significantly increased over the study period, while HTx showed a modest but non-significant rise. In a large nationwide cohort, all-cause and CV-mortality among AdvHFrEF patients markedly declined over the past 20 years, potentially reflecting improvements in treatments. Despite progress, significant opportunities remain to improve access to and adoption of advanced therapies.
中文摘要:晚期心力衰竭(AdvHF)仍是重大临床难题,而关于晚期心衰患者的当代真实世界流行病学数据有限。本研究旨在评估瑞典射血分数降低的晚期心衰(AdvHFrEF)患者在临床特征、结局以及左心室辅助装置(LVAD)和心脏移植使用方面20年的变化趋势。2003年至2022年间,瑞典心衰登记中纳入的5323例患者(中位年龄76岁,四分位距68–82岁,女性23%)符合改良ESC-HFA晚期心衰标准(NYHA III–IV级、EF<30%、6个月内至少1次心衰住院)。其中29%符合晚期心衰治疗条件(中位年龄63岁,四分位距57–67岁,女性18%),附加标准为年龄≤70岁、5年内未接受透析、3年内无活动性癌症。1年结局(全因死亡、心血管死亡、非心血管死亡、心脏移植和LVAD植入)的未校正时间趋势以估计年百分比变化(eAPC)表示。研究期间,总体队列1年全因死亡率显著下降(eAPC -3.8;95%CI -5.3至-2.2),符合晚期心衰治疗条件的患者同样下降(eAPC -3.2;95%CI -6.3至-0.1)。这些改善主要源于心血管死亡的减少(总体队列:eAPC -4.3;95%CI -6.0至-2.6;符合治疗条件队列:eAPC -5.6,95%CI -9.4至-1.7)。研究期间LVAD使用显著增加,心脏移植呈小幅上升但无统计学意义。在这一大型全国性队列中,AdvHFrEF患者的全因死亡和心血管死亡在过去20年间明显下降,可能反映了治疗的进步。尽管取得进展,在改善晚期治疗的获取与推广方面仍有很大空间。
To evaluate the comparative effectiveness of semaglutide versus dulaglutide or liraglutide in patients with diabetes receiving maintenance hemodialysis. Using 2011-2022 U.S. Renal Data System and Medicare data, we emulated a target trial evaluating semaglutide versus dulaglutide or liraglutide in patients receiving hemodialysis. Overlap weights were used to adjust for confounders. Fine-Gray models were used to assess death on dialysis and hospitalization. A generalized estimating equation was used for repeated measures of body weight. We identified 1,312 semaglutide and 2,601 dulaglutide or liraglutide users. After overlap weighting, the effective sample size was 3,200 patients (mean age 61; 63% White; 28% Black; 52% male; median [interquartile range] BMI 34 [29-40] kg/m2; median follow-up 1.1 [0.6-1.9] years). Semaglutide versus dulaglutide or liraglutide was associated with a mortality on dialysis subdistribution hazard ratio (sHR) of 0.82 (95% CI 0.70-0.97; 1-year cumulative incidence 11% vs. 13%) and all-cause hospitalization sHR of 0.91 (95% CI 0.83-0.99; 1-year incidence 57% vs. 62%). Body weight loss was higher with semaglutide (-4.8%, 95% CI -5.3% to -4.2%) at 1 year vs. -3.4%, 95% CI -3.9% to -3.1%). Direct comparisons of semaglutide versus dulaglutide showed similar results for mortality (sHR 0.82, 95% CI 0.69-0.97) and hospitalization (sHR 0.88, 95% CI 0.81-0.97), but semaglutide versus liraglutide showed no statistically significant benefit for mortality or hospitalization. Among patients with diabetes receiving hemodialysis and equipoise between semaglutide and dulaglutide or liraglutide, semaglutide may be the preferred glucagon-like peptide 1 agent compared with dulaglutide.
中文摘要:评估司美格鲁肽与度拉糖肽或利拉鲁肽在接受维持性血液透析的糖尿病患者中的比较有效性。利用2011—2022年美国肾脏数据系统与Medicare数据,在血液透析患者中模拟一项比较司美格鲁肽与度拉糖肽或利拉鲁肽的目标试验。采用重叠权重校正混杂因素。采用Fine-Gray模型评估透析中死亡与住院。采用广义估计方程分析重复测量的体重。共识别1312例司美格鲁肽使用者和2601例度拉糖肽或利拉鲁肽使用者。重叠加权后有效样本量为3200例患者(平均年龄61岁;白人63%;黑人28%;男性52%;体重指数中位数[四分位距]34[29-40] kg/m2;随访时间中位数1.1[0.6-1.9]年)。与度拉糖肽或利拉鲁肽相比,司美格鲁肽与透析中死亡的亚分布风险比0.82(95% CI 0.70-0.97;1年累积发生率11%对13%)及全因住院亚分布风险比0.91(95% CI 0.83-0.99;1年发生率57%对62%)相关。1年时司美格鲁肽组体重下降幅度更大(-4.8%,95% CI -5.3%至-4.2%),对照组为-3.4%(95% CI -3.9%至-3.1%)。司美格鲁肽与度拉糖肽直接比较,死亡(sHR 0.82,95% CI 0.69-0.97)和住院(sHR 0.88,95% CI 0.81-0.97)结果相似,但司美格鲁肽与利拉鲁肽比较未显示死亡或住院方面有统计学显著获益。在接受血液透析且司美格鲁肽与度拉糖肽或利拉鲁肽之间存在临床均势的糖尿病患者中,与度拉糖肽相比,司美格鲁肽可能是更优选的胰高糖素样肽-1药物。
3肾移植 (2篇)
临床研究 (2篇)
Alloreactivity after kidney transplantation occurs via both memory responses resulting from prior sensitization and de novo responses that develop due to donor-recipient disparity for the human leukocyte antigen (HLA) complex. HLA compatibility (absence of HLA-DSA) and the degree of HLA matching inform on the likelihood of allorecognition that can cause allograft rejection and allograft loss, and are therefore the two pillars of alloimmune risk assessment. Over the past decades, the detection of anti-HLA antibodies has become more sensitive and specific through single antigen bead testing, and advances in HLA typing from serology to DNA level have been instrumental for more detailed analysis of HLA compatibility. Nonetheless, alloimmune risk stratification using antigen-level HLA data has limited ability to accurately predict the risk of de novo anti-HLA responses and long-term graft outcome after transplantation, especially on the individual patient level. Aiming to improve long-term outcomes by improving HLA matching, HLA molecular mismatch algorithms have been developed. In this review, we discuss the advances, clinical evidence, limitations and clinical implementability of HLA molecular mismatch analysis to increase precision in alloimmune risk stratification in kidney transplantation. In addition, we provide an overview of the different molecular mismatch tools and their potential application in personalized medicine, such as organ allocation, criteria for donor acceptance and individualized immunosuppression.
中文摘要:肾移植后的同种免疫反应既来自既往致敏形成的记忆性应答,也来自供受者人类白细胞抗原(HLA)复合物差异所引发的新生应答。HLA相容性(HLA-DSA阴性)与HLA匹配程度可提示发生同种识别的可能性,而这种识别可导致移植物排斥和移植物丢失,因此二者构成同种免疫风险评估的两大支柱。过去数十年间,单抗原微珠检测使抗HLA抗体检测的敏感性和特异性提高,HLA分型从血清学进展至DNA水平,为更细致分析HLA相容性提供了关键手段。然而,基于抗原水平HLA数据的同种免疫风险分层在准确预测新生抗HLA应答风险及移植后长期移植物结局方面能力有限,尤其在个体患者层面。为通过改善HLA匹配提高长期结局,HLA分子错配算法得以开发。本综述讨论HLA分子错配分析在提高肾移植同种免疫风险分层精准度方面的进展、临床证据、局限性和临床可实施性。同时概述不同分子错配工具及其在个体化医疗中的潜在应用,如器官分配、供者接受标准和个体化免疫抑制。
Pain after kidney transplantation is often severe, and graft function constrains the use of systemic analgesia. Previous syntheses of regional techniques pooled them as a class, combined donors with recipients, and did not use a minimal clinically important difference (MCID). We searched PubMed, Embase, and CENTRAL through 5 September 2026 for randomised trials of regional analgesia in adult kidney transplant recipients (PROSPERO CRD420261478933); a trial-registry search and network meta-analysis were added post hoc. Bayesian random-effects models with MCID-scaled priors yielded posterior probabilities of benefit and of exceeding the MCID, and certainty of evidence was assessed using the GRADE framework. Fourteen trials (903 participants) were included. Only quadratus lumborum (QL) and transversus abdominis plane (TAP) blocks could be pooled against control. Both yielded lower pain at every pooled time point, but no pairwise pain comparison reached 80% probability of exceeding the 1.0 point MCID. Opioid consumption at 24 h was lower with the QL block (-15.5 morphine milligram equivalents; 95% credible interval -23.6 to -6.7) and the TAP block (-10.5; -14.4 to -5.5), with each reduction exceeding the 5 mg MCID with a probability >97%. In the network meta-analysis, no difference between QL and TAP blocks in pain or opioid consumption reached 80% probability of exceeding the MCID. Graft function and safety data were too sparse to pool. Twelve eligible registered trials were unpublished; certainty of evidence was very low. Quadrtus lumborum and transversus abdominus plane blocks reduce pain and opioid consumption at 24 h, but only the reduction in opioid consumption has a high probability of being clinically important. Certainty of evidence is very low; no technique is preferred, and effects on graft function are unknown.
中文摘要:肾移植术后疼痛常较严重,而移植物功能限制了全身镇痛药的使用。既往对区域镇痛技术的汇总分析将其作为一类技术合并,并将供者与受者合并,且未采用最小临床重要差值(MCID)。检索PubMed、Embase和CENTRAL至2026年9月5日,纳入成人肾移植受者区域镇痛的随机对照试验(PROSPERO CRD420261478933);试验注册库检索和网络荟萃分析为事后补充。采用按MCID缩放的先验的贝叶斯随机效应模型,获得获益及超过MCID的后验概率,并用GRADE框架评估证据确定性。共纳入14项试验(903例受者)。仅腰方肌(QL)阻滞和腹横肌平面(TAP)阻滞可与对照合并分析。两种阻滞在所有合并时间点均降低疼痛,但任何两两疼痛比较达到超过1.0分MCID的概率均未达80%。24小时阿片类药物消耗量在QL阻滞组更低(-15.5吗啡毫克当量,95%可信区间-23.6至-6.7),TAP阻滞组也更低(-10.5,-14.4至-5.5),每项降低超过5 mg MCID的概率均>97%。网络荟萃分析中,QL与TAP阻滞在疼痛或阿片消耗上的差异达到超过MCID概率80%的均无。移植物功能和安全性数据过少,无法合并。12项符合条件的注册试验未发表;证据确定性极低。QL和TAP阻滞可降低24小时疼痛和阿片消耗,但仅阿片消耗降低具有较高概率为临床重要。证据确定性极低;无技术被优先推荐,对移植物功能的影响未知。
4心肾代谢共病 (1篇)
临床研究 (1篇)
Physical frailty has been linked to cardiovascular-kidney-metabolic (CKM) multimorbidity, but the role of cognitive frailty and its dynamic changes in CKM progression remains unclear. We investigated the associations of baseline cognitive frailty and changes in cognitive frailty status with incident CKM multimorbidity. This cohort study included participants aged ≥45 years from the CHARLS (2011-2018). Cognitive frailty was classified as Robust, reversible cognitive frailty (RCF), or potentially reversible cognitive frailty (PRCF). A five-level score quantified the magnitude of cognitive change (Δscore). CKM multimorbidity was defined as ≥2 of cardiovascular disease, chronic kidney disease, and metabolic disease. Cox models and trend tests estimated hazard ratios (HRs) and 95% CIs. Among 9,816 participants, 3,836 were included in baseline CKM analysis and 1,891 in transition analysis. Both RCF (HR=2.74, 95%CI:2.25-3.34) and PRCF (HR=2.51, 95%CI:1.96-3.21) were associated with increased CKM risk (both P<0.001). Cognitive status provided additional risk stratification beyond physical frailty. RCF-to-Robust improvement reduced CKM risk by 56% (HR=0.44, 95%CI:0.23-0.85, P=0.015), while deterioration markedly increased risk (HR≈5.3, P<0.001). The Δscore trend test showed a significant dose-response relationship (P<0.001). Substantial improvement (Δscore=-3) significantly reduced risk, whereas minor improvements showed protective trends without statistical significance. Cognitive frailty is independently associated with CKM multimorbidity progression. Within each direction of cognitive change, the magnitude of change provided additional prognostic information beyond direction alone. These findings support the brain-CKM interconnection framework and suggest cognitive screening should be considered in CKM prevention strategies. Cognitive frailty-a condition where physical decline and memory problems occur together-is common in older adults. In this study, we analysed data from nearly 10,000 middle-aged and older adults in China to understand whether cognitive frailty increases the risk of developing cardiovascular-kidney-metabolic (CKM) multimorbidity, a cluster of conditions including heart disease, kidney disease, and diabetes. We found that people with cognitive frailty had significantly higher risks of developing CKM multimorbidity. More importantly, we found that the magnitude of change in cognitive function added prognostic information on top of its direction-greater worsening tracked with higher CKM risk. These findings suggest that monitoring changes in cognitive function over time could help identify individuals at high risk of CKM multimorbidity, and that interventions aimed at improving cognitive health may need to achieve meaningful improvement to reduce this risk.
中文摘要:身体衰弱与心血管-肾脏-代谢(CKM)共病相关,但认知衰弱及其动态变化在CKM进展中的作用仍不清楚。本研究分析基线认知衰弱及认知衰弱状态变化与新发CKM共病的关联。队列纳入CHARLS 2011—2018年年龄≥45岁的参与者。认知衰弱分为稳健、可逆性认知衰弱(RCF)和潜在可逆性认知衰弱(PRCF)。采用五级评分量化认知变化幅度(Δscore)。CKM共病定义为心血管疾病、慢性肾脏病和代谢性疾病中至少2种。采用Cox模型和趋势检验估计风险比(HR)及95%置信区间(CI)。9816名参与者中,3836名纳入基线CKM分析,1891名纳入状态转换分析。RCF(HR=2.74,95%CI:2.25-3.34)和PRCF(HR=2.51,95%CI:1.96-3.21)均与CKM风险升高相关(均P<0.001)。认知状态在身体衰弱之外提供了额外风险分层。RCF转为稳健使CKM风险降低56%(HR=0.44,95%CI:0.23-0.85,P=0.015),而恶化显著增加风险(HR≈5.3,P<0.001)。Δscore趋势检验显示显著剂量反应关系(P<0.001)。大幅改善(Δscore=-3)显著降低风险,小幅改善呈保护趋势但无统计学显著性。认知衰弱与CKM共病进展独立相关。在认知变化任一方向上,变化幅度均在方向之外提供额外预后信息。这些发现支持脑-CKM相互联系框架,并提示CKM预防策略应考虑认知筛查。认知衰弱指身体衰退与记忆问题同时出现,在老年人中常见。本研究分析中国近1万名中老年人数据,以了解认知衰弱是否增加心血管-肾脏-代谢(CKM)共病风险,该共病包括心脏病、肾脏病和糖尿病等疾病组合。结果发现,认知衰弱者发生CKM共病的风险显著更高。更重要的是,认知功能变化幅度在变化方向之外提供预后信息,恶化程度越大,CKM风险越高。这些发现提示,随时间监测认知功能变化有助于识别CKM共病高风险个体,旨在改善认知健康的干预可能需要达到有意义的改善才能降低这一风险。
5高血压/电解质/酸碱 (1篇)
临床研究 (1篇)
Hypertension affects over 1.3 billion people worldwide and is the leading modifiable cause of cardiovascular morbidity and mortality. Approximately one-third of individuals with hypertension exhibit a low-renin phenotype, a clinically heterogeneous subgroup in whom the underlying etiology remains uncharacterized in most cases. Among its mechanistic contributors, non-classical apparent mineralocorticoid excess (NC-AME), defined by partial insufficiency of 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2), represents a prevalent and underrecognized cause of cortisol-mediated mineralocorticoid receptor overactivation that has, to date, lacked a formal clinical definition, standardized diagnostic criteria, or evidence-based therapeutic framework. This Scientific Statement addresses that gap. The panel formally defines NC-AME as a syndrome of partial 11β-HSD2 insufficiency occurring in the absence of biallelic HSD11B2 variants, biochemically characterized by an elevated cortisol-to-cortisone (F/E) ratio and low cortisone concentration, and typically associated with low plasma renin, normal-to-low aldosterone, and elevated blood pressure. The Statement consolidates evidence across three mechanistic domains, genetic and epigenetic dysregulation of HSD11B2, endogenous and exogenous enzyme inhibition, and patient-specific alterations (i.e. age, sex, renal function), and proposes both a structured, an LC-MS/MS-based diagnostic algorithm, and a resource-adapted diagnostic approach. Mineralocorticoid receptor antagonists are endorsed as mechanism-directed first-line therapy, with blood pressure and renin normalization as co-primary treatment targets. Acquired and reversible causes are classified separately to guide clinical management. A research agenda is advanced to drive threshold standardization, multicenter validation, and integration of NC-AME into hypertension guidelines across endocrinology, cardiology, and nephrology.
中文摘要:高血压影响全球超过13亿人,是心血管疾病发病和死亡最主要的可干预原因。约三分之一高血压患者表现为低肾素表型,这一临床异质性亚组中多数病例的潜在病因仍未明确。非经典型表观盐皮质激素过多(NC-AME)由11β-羟类固醇脱氢酶2型(11β-HSD2)部分不足所定义,是皮质醇介导的盐皮质激素受体过度激活的常见但认识不足的原因;迄今缺乏正式临床定义、标准化诊断标准或循证治疗框架。本科学声明旨在填补这一空白。专家组将NC-AME正式定义为:在无HSD11B2双等位基因变异的情况下发生的部分性11β-HSD2不足综合征,生化特征为皮质醇与可的松比值(F/E)升高、可的松浓度降低,通常伴血浆肾素降低、醛固酮正常至降低及血压升高。声明整合了三个机制领域的证据:HSD11B2的遗传与表观遗传调控异常、内源性和外源性酶抑制、患者个体特异性改变(即年龄、性别、肾功能),并提出基于LC-MS/MS的结构化诊断流程,以及一种适应资源条件的诊断路径。盐皮质激素受体拮抗剂被推荐为机制导向的一线治疗,血压和肾素正常化作为共同主要治疗目标。获得性和可逆性病因被单独分类,以指导临床管理。声明提出研究议程,以推动阈值标准化、多中心验证,并将NC-AME纳入内分泌学、心脏病学和肾脏病学的高血压指南。
6急性肾损伤 AKI (1篇)
基础研究 (1篇)
Acute kidney injury (AKI) affects ∼20% of hospitalized patients and is traditionally viewed as a transient complication of acute illness. Evidence suggests that AKI can initiate long-term renal and cardiovascular disease, even when kidney function appears to recover. Survivors of AKI face increased risks of CKD, heart failure, myocardial infarction, and premature mortality, yet post-AKI care remains poorly defined. We synthesize emerging mechanistic and clinical evidence linking AKI to systemic cardiorenal disease and discuss how biomarkers, imaging, and clinical risk prediction may enable identification of high-risk patients and support translational strategies to prevent progression to chronic disease.
中文摘要:急性肾损伤(AKI)影响约20%的住院患者,传统上被视为急性疾病的短暂并发症。证据提示,即使肾功能看似恢复,AKI仍可启动长期肾脏和心血管疾病。AKI存活者面临慢性肾脏病、心力衰竭、心肌梗死和过早死亡风险增加,而AKI后照护仍缺乏明确规范。我们综合新出现的机制与临床证据,将AKI与全身性心肾疾病联系起来,并讨论生物标志物、影像学和临床风险预测如何识别高风险患者,支持阻止向慢性疾病进展的转化策略。
7心肾代谢 (1篇)
临床研究 (1篇)
Cardiometabolic diseases increasingly manifest as interconnected dysfunction across the heart, vasculature, kidneys, liver, and metabolic system. The global rise in obesity, insulin resistance, and diabetes, together with therapies benefiting multiple organs, has reshaped the epidemiology and understanding of cardiometabolic disease, exposing the limitations of organ-specific or single-stage approaches. The cardioVascular-kidney-liver-metabolic (CVKLM) framework is a multidimensional staging system in which cardiac, vascular, kidney, liver, and metabolic involvement are graded independently from absent to advanced. Analogous to tumour-node-metastasis staging, it provides a standardized language describing disease severity within each organ and its distribution across organs. Rather than replacing existing classifications, CVKLM integrates universal heart failure stages, validated vascular risk assessment, KDIGO chronic kidney disease stratification, contemporary metabolic dysfunction-associated steatotic liver disease (MASLD) and advanced liver disease criteria, and current definitions of diabetes and clinical obesity. Unlike hierarchical frameworks assigning a single overall stage, CVKLM preserves organ-specific information and records coexisting abnormalities across domains. Intended for clinical and research phenotyping and staging rather than as a validated global risk score, it may facilitate systematic recognition of concomitant organ disease, support existing organ-specific diagnostic, referral, and treatment pathways, and provide a standardized taxonomy for observational studies and clinical trials. The prognostic significance of CVKLM profiles, their incremental value beyond established risk tools, and their clinical utility remain to be established. By integrating these domains within a common architecture, CVKLM offers a pragmatic framework spanning the full spectrum of cardiometabolic disease, from preclinical involvement to advanced multiorgan failure.
中文摘要:心血管代谢疾病日益表现为心脏、血管、肾脏、肝脏和代谢系统相互关联的功能障碍。全球肥胖、胰岛素抵抗和糖尿病的增加,以及可惠及多个器官的治疗,改变了心血管代谢疾病的流行病学与认识,也暴露出按器官或单一分期方法的局限。CVKLM框架是一种多维分期系统,其中心脏、血管、肾脏、肝脏和代谢受累分别从无到晚期独立分级。类似肿瘤-淋巴结-转移分期,它提供标准化语言,描述每个器官内的疾病严重程度及其跨器官分布。CVKLM并非替代现有分类,而是整合通用心力衰竭分期、经验证的血管风险评估、KDIGO慢性肾脏病分层、当代代谢功能障碍相关脂肪性肝病(MASLD)及晚期肝病标准,以及当前糖尿病和临床肥胖定义。与赋予单一总体分期的层级框架不同,CVKLM保留器官特异性信息,并记录各领域并存的异常。它旨在用于临床和研究表型与分期,而非作为经验证的全局风险评分;可促进对并存器官疾病的系统识别,支持现有器官特异性诊断、转诊和治疗路径,并为观察性研究和临床试验提供标准化分类体系。CVKLM分型的预后意义、其在现有风险工具之外的增量价值及临床实用性尚待确定。通过将上述领域整合于共同架构,CVKLM提供了一个覆盖心血管代谢疾病全谱的实用框架,从临床前受累到晚期多器官衰竭。
8糖尿病 (1篇)
临床研究 (1篇)
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have demonstrated cardiorenal benefits in individuals with type 2 diabetes, but safety data in older adults remain limited. We evaluated the real-world safety of SGLT2is compared with dipeptidyl peptidase 4 inhibitors (DPP-4is) among individuals aged ≥75 years with type 2 diabetes. We conducted a population-based, active-comparator, new-user cohort study using administrative health databases from British Columbia, Canada. We included individuals aged ≥75 years with type 2 diabetes initiating SGLT2is or DPP-4is between 1 January 2021 and 31 December 2023. Primary outcomes were infection, diabetic ketoacidosis, acute kidney injury, fall, fracture, and all-cause hospitalization. Cox regression with propensity score-based standardized mortality ratio weighting was used to estimate hazard ratios (HRs). The study included 4,997 SGLT2i initiators (median age, 79 years; 37% women) and 1,289 DPP-4i initiators (median age, 82 years; 50% women). Compared with DPP-4i initiation, SGLT2i initiation was associated with lower risks of acute kidney injury (HR 0.76, 95% CI 0.60-0.95) and all-cause hospitalization (HR 0.87, 95% CI 0.77-0.98), with no difference in risk of infection. No differences were observed in risk of diabetic ketoacidosis, falls, or fractures, although CIs were compatible with both benefit and harm. In individuals aged ≥75 years with type 2 diabetes, SGLT2i initiation was not associated with increased risk of harm compared with DPP-4i initiation, although estimates were imprecise for some outcomes. These findings may support consideration of SGLT2is as a treatment option in this population.
中文摘要:钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)已在2型糖尿病患者中显示心肾获益,但老年人群的安全性数据仍有限。我们在年龄≥75岁的2型糖尿病患者中,比较SGLT2i与二肽基肽酶4抑制剂(DPP-4i)的真实世界安全性。采用加拿大不列颠哥伦比亚省的行政健康数据库,开展基于人群、活性对照、新用药者队列研究。纳入2021年1月1日至2023年12月31日期间开始使用SGLT2i或DPP-4i、年龄≥75岁的2型糖尿病患者。主要结局为感染、糖尿病酮症酸中毒、急性肾损伤、跌倒、骨折和全因住院。使用基于倾向评分的标准化死亡比加权的Cox回归估计风险比(HR)。研究纳入4,997例SGLT2i起始者(中位年龄79岁;女性37%)和1,289例DPP-4i起始者(中位年龄82岁;女性50%)。与开始使用DPP-4i相比,开始使用SGLT2i与急性肾损伤风险降低(HR 0.76,95% CI 0.60-0.95)和全因住院风险降低(HR 0.87,95% CI 0.77-0.98)相关,感染风险无差异。糖尿病酮症酸中毒、跌倒或骨折风险未见差异,但置信区间与获益和危害均相容。在年龄≥75岁的2型糖尿病患者中,与开始使用DPP-4i相比,开始使用SGLT2i未伴随危害风险增加,尽管部分结局的估计不精确。这些发现可能支持将SGLT2i作为该人群的治疗选择予以考虑。
9肾小球疾病 (1篇)
临床研究 (1篇)
Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis with incompletely understood pathogenesis, hindering therapeutics development and contributing to high rates of end-stage kidney disease and mortality. We aimed to construct a spatially resolved cellular and molecular atlas of SRC kidneys to identify disease-specific microenvironments and therapeutic targets. Kidney biopsy samples from 12 patients with SRC manifesting histopathologically as thrombotic microangiopathy (TMA), 6 patients with lupus nephritis (LN), and 3 normal kidneys were analysed by spatial transcriptomics (discovery cohort), and the findings were validated in an expanded cohort by multiplexed imaging. Spatial organization and cellular phenotypes were analysed across histopathologically defined regions. Multiplexed imaging demonstrated a pathological triad of TMA, immune infiltration, and fibrotic remodelling in SRC kidneys. SRC and LN shared activation of the complement cascade, type I interferon signalling, and fibrotic remodelling. However, SRC exhibited a distinct vascular-hypoxic axis. Spatial analyses revealed disease-specific glomerular niches at the interface between renal parenchymal cells and prominent myeloid immune cells. We demonstrated dynamic molecular signatures that progressed from mild lesions through overt SRC-associated pathological changes (glomerular TMA or arterial injury) to chronic lesions in each histopathologically defined region. Multiple pathological pathways were already upregulated in mild lesions, with selective enrichment in glomerular TMA and arterial injury, ultimately converging on injury and remodelling programmes in the chronic lesions. This study advances our understanding of SRC beyond histopathology to the molecular and cellular landscape, providing an omics-driven framework to accelerate therapeutic target discovery in this rare, devastating disease.
中文摘要:硬皮病肾危象(SRC)是系统性硬化症的一种危及生命的并发症,其发病机制尚未完全阐明,阻碍了治疗开发,并导致终末期肾病和死亡的高发生率。我们旨在构建SRC肾脏的空间分辨细胞与分子图谱,以识别疾病特异性微环境和治疗靶点。研究对12例组织病理学表现为血栓性微血管病(TMA)的SRC患者、6例狼疮肾炎(LN)患者和3例正常肾脏的肾活检样本进行空间转录组学分析(发现队列),并在扩大队列中通过多重成像验证结果。分析组织病理学定义区域内各区域的空间组织和细胞表型。多重成像显示SRC肾脏存在TMA、免疫浸润和纤维化重塑的病理三联征。SRC与LN均显示补体级联、I型干扰素信号和纤维化重塑的激活。但SRC表现出独特的血管-缺氧轴。空间分析揭示了位于肾实质细胞与显著髓系免疫细胞交界处的疾病特异性肾小球微环境。我们展示了从轻度病变进展为明确的SRC相关病理改变(肾小球TMA或动脉损伤)再至各组织病理学定义区域慢性病变的动态分子特征。多条病理通路在轻度病变中已上调,并在肾小球TMA和动脉损伤中选择性富集,最终汇聚于慢性病变中的损伤和重塑程序。本研究将SRC的理解从组织病理学推进到分子和细胞层面,为加速这种罕见且毁灭性疾病治疗靶点发现提供了组学驱动的框架。